Elda Tagliabue

List of Publications by Year in Descending Order

198 papers	8,734 citations	50 h-index	87 g-index
210 ext. papers	9,825 ext. citations	6.8 avg, IF	5.66 L-index

#	Paper	IF	Citations
198	Worldwide SARS-CoV-2 haplotype distribution in early pandemic.. *PLoS ONE*, **2022**, 17, e0263705	3.7	
197	BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.. *Cellular Oncology (Dordrecht)*, **2022**, 1	7.2	1
196	Aerosol 1,25-dihydroxyvitamin D3 supplementation: A strategy to boost anti-tumor innate immune activity. *PLoS ONE*, **2021**, 16, e0248789	3.7	0
195	Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	10
194	Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay. *Cancers*, **2021**, 13,	6.6	2
193	Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer. *Cancer Research*, **2021**, 81, 2195-2206	10.1	12
192	A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis. *Molecular Oncology*, **2021**, 15, 1345-1357	7.9	2
191	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. *Clinical Cancer Research*, **2021**, 27, 6307-6313	12.9	0
190	Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth. *IScience*, **2021**, 24, 103012	6.1	11
189	Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 732192	5.7	1
188	What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.. *Cancer Medicine*, **2021**,	4.8	1
187	Deep Into Breast Cancer Heterogeneity to Increase Immunotherapeutic Effectiveness.. *JCO Precision Oncology*, **2020**, 4, 1267-1268	3.6	1
186	Infrared Spectroscopic Imaging Visualizes a Prognostic Extracellular Matrix-Related Signature in Breast Cancer. *Scientific Reports*, **2020**, 10, 5442	4.9	4
185	Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure. *Cells*, **2020**, 9,	7.9	13
184	Adipocytes in Breast Cancer, the Thick and the Thin. *Cells*, **2020**, 9,	7.9	35
183	Combined targeting of EGFR and HER2 against prostate cancer stem cells. *Cancer Biology and Therapy*, **2020**, 21, 463-475	4.6	6
182	TLR3 Expression Induces Apoptosis in Human Non-Small-Cell Lung Cancer. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	20

181	ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab. *Scientific Reports*, **2020**, 10, 3016	4.9	6
180	Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment. *Cells*, **2020**, 9,	7.9	3
179	The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. *Cellular and Molecular Life Sciences*, **2020**, 77, 2739-2749	10.3	51
178	Mexican Extracts Decrease Lipogenesis Modulating Transcriptional Metabolic Networks and Gut Microbiota in C57BL/6 Mice Fed with a High-Cholesterol Diet. *Nutrients*, **2020**, 13,	6.7	6
177	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don₽) know. *Journal of Experimental and Clinical Cancer Research*, **2020**, 39, 236	12.8	12
176	Inhibition of the Wnt Signalling Pathway: An Avenue to Control Breast Cancer Aggressiveness. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
175	Rapid, Cost-Effective Peptide/Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples. *ACS Sensors*, **2020**, 5, 3109-3115	9.2	4
174	MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer. *Cancers*, **2020**, 12,	6.6	7
173	Infiltrating Mast Cell-Mediated Stimulation of Estrogen Receptor Activity in Breast Cancer Cells Promotes the Luminal Phenotype. *Cancer Research*, **2020**, 80, 2311-2324	10.1	7
172	Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. *Scientific Reports*, **2019**, 9, 14288	4.9	8
171	Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors. *Cells*, **2019**, 8,	7.9	42
170	WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. *Oncogene*, **2019**, 38, 4047-4060	9.2	101
169	The landscape of d16HER2 splice variant expression across HER2-positive cancers. *Scientific Reports* , **2019**, 9, 3545	4.9	18
168	Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors. *Cells*, **2019**, 8,	7.9	11
167	Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer. *Journal of Cellular Physiology*, **2019**, 234, 1768-1779	7	25
166	Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. *Cellular Oncology (Dordrecht)*, **2019**, 42, 815-828	7.2	9
165	Local Administration of Caloric Restriction Mimetics to Promote the Immune Control of Lung Metastases. *Journal of Immunology Research*, **2019**, 2019, 2015892	4.5	11
164	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. *European Journal of Cancer*, **2019**, 118, 1-9	7.5	8

163	The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?. *Cancers*, **2019**, 11,	6.6	9
162	Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation. *Cancers*, **2019**, 11,	6.6	21
161	Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death. *Molecular Oncology*, **2019**, 13, 909-927	7.9	19
160	HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. *OncoImmunology*, **2019**, 8, e1512942	7.2	25
159	Extracellular matrix proteins as diagnostic markers of breast carcinoma. *Journal of Cellular Physiology*, **2018**, 233, 6280-6290	7	28
158	cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells. *Cell Death and Differentiation*, **2018**, 25, 2147-2164	12.7	11
157	MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer. *Breast*, **2018**, 39, 46-52	3.6	5
156	The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer. *BMC Cancer*, **2018**, 18, 586	4.8	11
155	MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. *Oncotarget*, **2018**, 9, 27920-27928	3.3	12
154	Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. *British Journal of Cancer*, **2018**, 119, 1487-1494	8.7	15
153	Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases. *Cell Reports*, **2018**, 24, 3528-3538	10.6	67
152	ECM Remodeling in Breast Cancer with Different Grade: Contribution of 2D-DIGE Proteomics. *Proteomics*, **2018**, 18, e1800278	4.8	15
151	Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer. *BMC Cancer*, **2018**, 18, 899	4.8	22
150	Activation of NK cell cytotoxicity by aerosolized CpG-ODN/poly(I:C) against lung melanoma metastases is mediated by alveolar macrophages. *Cellular Immunology*, **2017**, 313, 52-58	4.4	18
149	Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation. *Seminars in Cancer Biology*, **2017**, 43, 74-89	12.7	271
148	Quantification of Circulating Cancer Biomarkers via Sensitive Topographic Measurements on Single Binder Nanoarrays. *ACS Omega*, **2017**, 2, 2618-2629	3.9	15
147	Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host. *Disease Markers*, **2017**, 2017, 7849108	3.2	15
146	Exploiting poly(I:C) to induce cancer cell apoptosis. *Cancer Biology and Therapy*, **2017**, 18, 747-756	4.6	59

145	Antibody-mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities. *FASEB Journal*, **2017**, 31, 5356-5370	0.9	7
144	Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. *Cancer Letters*, **2017**, 384, 94-100	9.9	96
143	Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer. *Oncogene*, **2017**, 36, 1721-1732	9.2	26
142	HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. *Oncotarget*, **2017**, 8, 54444-54458	3.3	10
141	Expression and prognostic significance of the autoimmune regulator gene in breast cancer cells. *Cell Cycle*, **2016**, 15, 3220-3229	4.7	8
140	CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. *Journal of Translational Medicine*, **2016**, 14, 25	8.5	14
139	Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge. *Future Oncology*, **2016**, 12, 1413-28	3.6	21
138	Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. *Oncotarget*, **2016**, 7, 255-65	3.3	28
137	miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. *Oncotarget*, **2016**, 7, 786-97	3.3	56
136	CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. *Oncotarget*, **2016**, 7, 69649-69665	3.3	25
135	Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study. *Breast Cancer Research and Treatment*, **2016**, 157, 179-89	4.4	27
134	Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. *Cell Reports*, **2016**, 17, 233-248	10.6	62
133	Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor. *OncoImmunology*, **2016**, 5, e1234571	7.2	24
132	Biomimicking of the Breast Tumor Microenvironment. *Current Molecular Biology Reports*, **2015**, 1, 71-76	2	2
131	Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression. *Seminars in Cancer Biology*, **2015**, 35, 3-10	12.7	104
130	Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment. *OncoImmunology*, **2015**, 4, e1040214	7.2	31
129	Secondary electrospray ionization-mass spectrometry and a novel statistical bioinformatic approach identifies a cancer-related profile in exhaled breath of breast cancer patients: a pilot study. *Journal of Breath Research*, **2015**, 9, 031001	3.1	18
128	Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype. *Cancer Medicine*, **2015**, 4, 1016-30	4.8	24

127	Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells. *Journal of Cellular Physiology*, **2015**, 230, 2661-70	7	11
126	Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. *Oncotarget*, **2015**, 6, 28173-82	3.3	20
125	Aerosol Delivery in the Treatment of Lung Cancer. *Current Cancer Drug Targets*, **2015**, 15, 604-12	2.8	13
124	Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. *Molecular Cancer*, **2014**, 13, 23	42.1	8
123	Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas. *International Journal of Cancer*, **2014**, 135, 2034-45	7.5	14
122	PDGFR and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. *Molecular Oncology*, **2014**, 8, 968-81	7.9	32
121	"Omics" and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas. *Frontiers in Oncology*, **2014**, 4, 334	5.3	1
120	Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab. *Annals of Oncology*, **2014**, 25, 1073-4	10.3	4
119	Maspin influences response to doxorubicin by changing the tumor microenvironment organization. *International Journal of Cancer*, **2014**, 134, 2789-97	7.5	12
118	Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98). *Cancer*, **2014**, 120, 885-93	6.4	51
117	Stromal responses among carcinomas--letter. *Clinical Cancer Research*, **2014**, 20, 1396	12.9	
116	Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab. *Cancer Research*, **2014**, 74, 6248-59	10.1	47
115	Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up. *Breast*, **2014**, 23, 334-40	3.6	1
114	High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors. *Journal of Translational Medicine*, **2013**, 11, 25	8.5	15
113	Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. *Breast Cancer Research and Treatment*, **2013**, 141, 101-10	4.4	22
112	Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. *International Journal of Cancer*, **2013**, 133, 383-93	7.5	16
111	EGFR through STAT3 modulates N63 expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas. *Journal of Cellular Physiology*, **2013**, 228, 871-8	7	21
110	microRNA: New Players in Metastatic Process **2013**,		2

109	FOXP3 expression in tumor cells and implications for cancer progression. *Journal of Cellular Physiology*, **2013**, 228, 30-5	7	68
108	Influence of fatty acid-free diet on mammary tumor development and growth rate in HER-2/Neu transgenic mice. *Journal of Cellular Physiology*, **2013**, 228, 242-9	7	6
107	Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. *PLoS ONE*, **2013**, 8, e56761	3.7	38
106	Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD). *PLoS ONE*, **2013**, 8, e58358	3.7	4
105	Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation. *PLoS ONE*, **2013**, 8, e58849	3.7	19
104	Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. *Journal of Cellular Physiology*, **2012**, 227, 658-67	7	325
103	Induction of Paneth cell degranulation by orally administered Toll-like receptor ligands. *Journal of Cellular Physiology*, **2012**, 227, 1107-13	7	50
102	PET prediction of response to trastuzumab in ErbB2-positive human xenograft model. *Journal of Nuclear Medicine*, **2012**, 53, 1654-5; author reply 1655-6	8.9	1
101	Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34+ cells in a xenograft model. *Breast Cancer Research and Treatment*, **2012**, 136, 457-67	4.4	3
100	Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. *Molecular Oncology*, **2012**, 6, 458-72	7.9	122
99	Activity and resistance of trastuzumab according to different clinical settings. *Cancer Treatment Reviews*, **2012**, 38, 212-7	14.4	25
98	Promise and failure of targeted therapy in breast cancer. *Frontiers in Bioscience - Scholar*, **2012**, 4, 356-74	2.4	2
97	Promise and failure of targeted therapy in breast cancer. *Frontiers in Bioscience - Scholar*, **2012**, S4, 356-374	2.4	4
96	Modulation of DNA repair genes induced by TLR9 agonists: A strategy to eliminate "altered" cells?. *OncoImmunology*, **2012**, 1, 258-259	7.2	4
95	Current and Future Developments in Cancer Therapy Research: miRNAs as New Promising Targets or Tools **2012**, 517-546		1
94	HER2 splice variants and their relevance in breast cancer. *Journal of Nucleic Acids Investigation*, **2011**, 2, 9		2
93	Do Pre-Diagnostic Drinking Habits Influence Breast Cancer Survival?. *Tumori*, **2011**, 97, 142-148	1.7	16
92	Breast cancer and microRNAs: therapeutic impact. *Breast*, **2011**, 20 Suppl 3, S63-70	3.6	80

91	Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. *Breast Cancer Research and Treatment*, **2011**, 128, 147-54	4.4	20
90	The HER2 World: Better Treatment Selection for Better Outcome. *Journal of the National Cancer Institute Monographs*, **2011**, 2011, 82-5	4.8	7
89	TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects. *Cancer Research*, **2011**, 71, 6382-90	10.1	31
88	Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. *Annals of Oncology*, **2011**, 22, 1886-93	10.3	19
87	International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). *Journal of the National Cancer Institute Monographs*, **2011**, 2011, 147-51	4.8	55
86	The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. *PLoS ONE*, **2011**, 6, e18727	3.7	55
85	Do pre-diagnostic drinking habits influence breast cancer survival?. *Tumori*, **2011**, 97, 142-8	1.7	14
84	Influence of lignans depletion on murine mammary gland morphology. *Nutrition and Cancer*, **2010**, 62, 237-42	2.8	3
83	Triple-negative breast cancer: present challenges and new perspectives. *Molecular Oncology*, **2010**, 4, 209-29	7.9	212
82	HER2 as a target for breast cancer therapy. *Expert Opinion on Biological Therapy*, **2010**, 10, 711-24	5.4	68
81	Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines. *Cancer Letters*, **2010**, 296, 206-15	9.9	9
80	Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. *Journal of Immunotherapy*, **2010**, 33, 8-15	5	19
79	Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. *BMC Cancer*, **2010**, 10, 378	4.8	43
78	Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. *Journal of Cellular Physiology*, **2010**, 225, 256-65	7	25
77	Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. *Cellular Oncology*, **2010**, 32, 361-72		38
76	microRNA-205 regulates HER3 in human breast cancer. *Cancer Research*, **2009**, 69, 2195-200	10.1	298
75	Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. *Clinical Cancer Research*, **2009**, 15, 2010-21	12.9	217
74	FOXP3 expression and overall survival in breast cancer. *Journal of Clinical Oncology*, **2009**, 27, 1746-52	2.2	225

73	MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. *European Journal of Cancer*, **2008**, 44, 2753-9	7.5	123
72	Folate in head and neck squamous cell cancer chemoprevention: purposely left out?. *Journal of Clinical Oncology*, **2008**, 26, 3463; author reply 3463-4	2.2	2
71	Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. *Annals of Oncology*, **2008**, 19, 1706-12	10.3	23
70	Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact. *Clinical Cancer Research*, **2008**, 14, 25-31	12.9	17
69	Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu. *Journal of Immunotherapy*, **2008**, 31, 537-44	5	13
68	Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. *Journal of Pathology*, **2008**, 214, 357-67	9.4	264
67	Matured human monocyte-derived dendritic cells (MoDCs) induce expansion of CD4+CD25+FOXP3+ T cells lacking regulatory properties. *Immunology Letters*, **2008**, 117, 106-13	4.1	5
66	Salad vegetables dietary pattern protects against HER-2-positive breast cancer: a prospective Italian study. *International Journal of Cancer*, **2007**, 121, 911-4	7.5	57
65	Relationship between p53 and p27 expression following HER2 signaling. *Breast*, **2007**, 16, 597-605	3.6	13
64	Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. *Cancer Research*, **2007**, 67, 11991-9	10.1	172
63	Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. *Annals of Oncology*, **2007**, 18, 601-2	10.3	22
62	Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections. *Cell Cycle*, **2007**, 6, 643-6	4.7	17
61	Regulation of breast cancer response to chemotherapy by fibulin-1. *Cancer Research*, **2007**, 67, 4271-7	10.1	55
60	Radiation effects on development of HER2-positive breast carcinomas. *Clinical Cancer Research*, **2007**, 13, 46-51	12.9	58
59	Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. *Cancer Research*, **2007**, 67, 5308-17	10.1	25
58	Diadenosines as FHIT-ness instructors. *Journal of Cellular Physiology*, **2006**, 208, 274-81	7	11
57	FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 18981-6	11.5	34
56	Influence of antibiotic treatment on breast carcinoma development in proto-neu transgenic mice. *Cancer Research*, **2006**, 66, 6219-24	10.1	32

55	Role of exon-16-deleted HER2 in breast carcinomas. *Endocrine-Related Cancer*, **2006**, 13, 221-32	5.7	91
54	Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. *European Journal of Cancer*, **2006**, 42, 1057-61	7.5	7
53	HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. *Journal of Cellular Physiology*, **2005**, 205, 10-8	7	27
52	The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. *Endocrine-Related Cancer*, **2005**, 12, 393-406	5.7	61
51	Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas. *BioTechniques*, **2005**, 39, 755-61	2.5	20
50	Apoptosis induction by trastuzumab: possible role of the core biopsy intervention. *Journal of Clinical Oncology*, **2005**, 23, 7238-40	2.2	7
49	Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. *Clinical Cancer Research*, **2004**, 10, 5650-5	12.9	400
48	Role of HER2/neu in tumor progression and therapy. *Cellular and Molecular Life Sciences*, **2004**, 61, 2965-78	18.3	110
47	Biologic and therapeutic role of HER2 in cancer. *Oncogene*, **2003**, 22, 6570-8	9.2	304
46	Role of HER2 in wound-induced breast carcinoma proliferation. *Lancet, The*, **2003**, 362, 527-33	40	129
45	HER2 and proliferation of wound-induced breast carcinoma. *Lancet, The*, **2003**, 362, 1503; author reply 1503	40	3
44	HER2 and proliferation of wound-induced breast carcinoma. *Lancet, The*, **2003**, 362, 1503	40	4
43	New insights into the role of extracellular matrix during tumor onset and progression. *Journal of Cellular Physiology*, **2002**, 192, 259-67	7	235
42	p53-dependent downregulation of metastasis-associated laminin receptor. *Oncogene*, **2002**, 21, 7478-87	9.2	30
41	HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. *Clinical Cancer Research*, **2002**, 8, 520-5	12.9	50
40	Identification of a novel function for 67-kDa laminin receptor: increase in laminin degradation rate and release of motility fragments. *Cancer Research*, **2002**, 62, 1321-5	10.1	57
39	The early relapse of premenopausal patients after surgery for node-positive breast carcinoma. *Breast Cancer Research and Treatment*, **2001**, 70, 155-6	4.4	9
38	Role of HER2 gene overexpression in breast carcinoma. *Journal of Cellular Physiology*, **2000**, 182, 150-62	7	218

37	Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo. *Oncogene*, **2000**, 19, 4979-87	9.2	71
36	Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. *Journal of Biological Chemistry*, **2000**, 275, 5388-94	5.4	49
35	Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle. *American Journal of Pathology*, **1999**, 155, 1543-7	5.8	20
34	The 67 kDa laminin receptor as a prognostic factor in human cancer. *Breast Cancer Research and Treatment*, **1998**, 52, 137-45	4.4	128
33	Formation of the 67-kDa laminin receptor by acylation of the precursor. *Journal of Cellular Biochemistry*, **1998**, 69, 244-51	4.7	93
32	Target molecules for immunotherapy of inflammatory breast carcinomas. *European Journal of Cancer*, **1998**, 34, 1982-3	7.5	9
31	Heregulin beta1 induces the down regulation and the ubiquitin-proteasome degradation pathway of p185HER2 oncoprotein. *FEBS Letters*, **1998**, 422, 129-31	3.8	15
30	The 67 kDa laminin receptor as a prognostic factor in human cancer **1998**, 227-235		
29	Co-regulation and physical association of the 67-kDa monomeric laminin receptor and the alpha6beta4 integrin. *Journal of Biological Chemistry*, **1997**, 272, 2342-5	5.4	70
28	Replacement of Fhit in cancer cells suppresses tumorigenicity. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 13771-6	11.5	303
27	Expression of bone sialoprotein in human lung cancer. *Calcified Tissue International*, **1997**, 61, 183-8	3.9	66
26	New insights into the metastasis-associated 67 kD laminin receptor. *Journal of Cellular Biochemistry* , **1997**, 67, 155-165	4.7	113
25	Shedding of the 67-kD laminin receptor by human cancer cells **1996**, 60, 226-234		19
24	Peptide G, containing the binding site of the 67-kDa laminin receptor, increases and stabilizes laminin binding to cancer cells. *Journal of Biological Chemistry*, **1996**, 271, 31179-84	5.4	34
23	Prognostic significance of laminin production in relation with its receptor expression in human breast carcinomas. *Breast Cancer Research and Treatment*, **1995**, 35, 195-9	4.4	29
22	Colocalization of the p185HER2 oncoprotein and integrin alpha 6 beta 4 in Calu-3 lung carcinoma cells. *Journal of Cellular Biochemistry*, **1994**, 55, 409-18	4.7	15
21	Relevance of antibody valency in EGF receptor modulation. *Scandinavian Journal of Immunology*, **1994**, 39, 453-8	3.4	6
20	Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with primary tumour prognostic features. *British Journal of Cancer*, **1994**, 69, 1126-9	8.7	49

19	Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. *Journal of the National Cancer Institute*, **1993**, 85, 398-402	9.7	123
18	Alteration of laminin production in small-cell lung carcinoma: possible correlation with the absence of the basement membrane. *Tumor Biology*, **1993**, 14, 279-87	2.9	3
17	Genetic changes in lung cancer. *Journal of Cellular Biochemistry*, **1993**, 17F, 237-48	4.7	20
16	Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency. *Cancer Immunology, Immunotherapy*, **1993**, 36, 397-402	7.4	14
15	p185 HER2/neu epitope mapping with murine monoclonal antibodies. *Hybridoma*, **1992**, 11, 267-76		28
14	Production and Characterization of two Monoclonal Antibodies Directed against the Integrin β1 Chain. *Tumori*, **1992**, 78, 1-4	1.7	18
13	Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression. *Clinical and Experimental Metastasis*, **1992**, 10, 379-86	4.7	52
12	Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification. *International Journal of Cancer*, **1991**, 47, 933-7	7.5	91
11	Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site. *Cancer Immunology, Immunotherapy*, **1991**, 34, 37-42	7.4	22
10	MOv18 Monoclonal Antibody in Diagnostic Applications: Capability to Recognize the Histotype of the Original Tumor. *Tumori*, **1990**, 76, 10-13	1.7	3
9	Monoclonal antibodies against doxorubicin. *International Journal of Cancer*, **1988**, 42, 798-802	7.5	14
8	Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. *International Journal of Cancer*, **1988**, 41, 609-15	7.5	63
7	Human carcinoma cell lines xenografted in athymic mice: biological and antigenic characteristics of an intraabdominal model. *Cancer Immunology, Immunotherapy*, **1987**, 24, 13-8	7.4	14
6	Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. *International Journal of Cancer*, **1987**, 39, 297-303	7.5	265
5	Improvement of tumor cell detection using a pool of monoclonal antibodies. *Hybridoma*, **1986**, 5, 107-15		24
4	Ricin A chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro. *Journal of the National Cancer Institute*, **1985**, 75, 831-9	9.7	37
3	Sensitivity enhancement of the cytologic detection of cancer cells in effusions by monoclonal antibodies. *American Journal of Clinical Pathology*, **1985**, 83, 571-6	1.9	30
2	Human renal antigen defined by a murine monoclonal antibody. *Journal of the National Cancer Institute*, **1984**, 73, 363-9	9.7	11

1	Immunocytochemical identification of breast carcinoma cells in effusions using a monoclonal antibody. *Journal of Clinical Pathology*, **1982**, 35, 1037	3.9	11